BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $529 from $570 and keeps a Neutral rating on the shares. Following quarterly results and the associated call, the firm is “modestly” lowering forecasts after incorporating the team’s comments on gross-to-net adjustments, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
- Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
- Paulson buys Solstice, exits Honeywell in Q4
- MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo